CFDE Data Portal | Search SAP30BP-AS1

	Label	Description
	SAP30BP-AS1 Gene (Entity type)	ENSG00000264270 - SAP30BP antisense RNA 1
	GSE195663 cisplatin 7 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE144443 0 V 6 NICOTINAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE197555 0 V 3 TRAMETINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE145195 PPP2R3B overexpression 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE168745 H-7 JHH-7 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE165548 gemcitabine 2 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 2 v 13 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE213588 trametinib NF1 8 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE178340 carfilzomib MM1.S 7 v 9 human dn Gene Set (Entity type)	A Gene Set from LINCS

SAP30BP-AS1

ENSG00000264270 - SAP30BP antisense RNA 1

GSE195663 cisplatin 7 v 1 human dn

A Gene Set from LINCS

GSE144443 0 V 6 NICOTINAMIDE MOUSE UP

A Gene Set from LINCS

GSE197555 0 V 3 TRAMETINIB HUMAN UP

A Gene Set from LINCS

GSE145195 PPP2R3B overexpression 0 v 1 human dn

A Gene Set from LINCS

GSE168745 H-7 JHH-7 0 v 1 human dn

A Gene Set from LINCS

GSE165548 gemcitabine 2 v 5 human up

A Gene Set from LINCS

GSE111247 temozolomide LN-308 2 v 13 human up

A Gene Set from LINCS

GSE213588 trametinib NF1 8 v 11 human dn

A Gene Set from LINCS

GSE178340 carfilzomib MM1.S 7 v 9 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.